India’s indigenous TB vaccine programme has reached a decisive stage, but the move towards human trials remains dependent on evidence, regulatory clearance and the ability to convert laboratory research into a public-health product. Koch Vac, developed by IIT Bhubaneswar and the Institute of Life Sciences in Bhubaneswar, has entered preclinical animal studies after its technology was transferred to Mumbai-based Tech Invention Lifecare Ltd.
The company is targeting human trials in the second half of 2027. That target is not an approval or a confirmed trial date. It depends on the completion of animal studies, the generation of additional data, the regulatory process and approvals from the relevant authorities. The distinction is important because vaccine development is not a single announcement but a sequence of scientific, administrative and manufacturing decisions.
The latest development was discussed at a national expert deliberation on “Advancing Bharat’s Indigenous TB Vaccine” in New Delhi on September 25. Researchers, clinicians and industry representatives reviewed the progress of Koch Vac and discussed the development roadmap. According to an IIT Bhubaneswar press statement cited by the Times of India, Tech Invention said it planned to begin the regulatory process and aimed to start human trials during the latter half of 2027.
Tech Invention director and CEO Syed S Ahmed said the company would first conduct animal trials, generate the required data and then seek approval before moving to human trials. He also said the company would work with the Institute of Life Sciences and IIT Bhubaneswar to optimise the candidate before engaging with regulators. The proposed human testing would proceed in three phases, subject to approval.
That sequence places Koch Vac at the transition between academic research and regulated product development. The candidate was jointly developed by Ashis Biswas of IIT Bhubaneswar and Sunil Kumar Raghav of the Institute of Life Sciences. Its technology was transferred to Tech Invention through a quadripartite licensing agreement signed in November 2025, with the National Research Development Corporation facilitating the arrangement.
The licensing agreement is significant because research institutions do not automatically become vaccine manufacturers or clinical-trial sponsors. A candidate has to move through an institutional and commercial pathway in which scientific work, intellectual-property arrangements, regulatory submissions, trial planning and eventual production capability are brought together. In this case, the agreement created a formal route for Tech Invention to take the candidate into the next phase while the two Bhubaneswar institutions continue to contribute to its development.
The available account also shows that the vaccine is still being refined. Experts at the New Delhi meeting discussed antigen design, epitope selection, adjuvant strategy, animal models, formulation and suitability for large-scale public-health programmes. These are not peripheral technical details. They determine what the vaccine is intended to do, how the immune response is generated, how it performs in testing and whether it can eventually be produced and deployed at the scale required for a national disease-control programme.
Koch Vac is designed to generate strong humoral and cell-mediated immune responses and enhance the protection offered by the Bacillus Calmette-Guérin vaccine. BCG remains the only licensed TB vaccine, according to the report, but its protection against pulmonary TB in adolescents and adults is limited. The development of a candidate intended to improve on that protection therefore addresses a gap in the existing vaccine landscape rather than simply adding another product to an established market.
The public-health need is substantial. The report, citing the World Health Organization, says TB claimed 1.23 million lives globally in 2024. That figure places the development of new vaccines within a continuing global health challenge. It also explains why the researchers and experts are discussing not only whether the candidate works, but whether its formulation and development pathway are suitable for large-scale public-health programmes.
The contrast between the scale of the disease burden and the early stage of Koch Vac is central to understanding the announcement. A candidate beginning animal studies is not yet evidence of efficacy in people. It is a scientific asset undergoing a process designed to establish whether it is safe and effective enough to enter successive stages of testing. The company’s stated target of late 2027 is consequently best understood as a development objective, not a guarantee of availability.
The proposed three-phase human-trial pathway is another indication of how far the programme must travel. The source does not provide trial sizes, locations, protocols or regulatory submission dates. It also does not establish when a vaccine could be licensed or supplied for routine use. Those details will depend on data generated during preclinical work and subsequent regulatory decisions. For now, the confirmed movement is from institutional development into animal studies, alongside preparations for the regulatory process.
This makes the role of the regulator particularly important. Ahmed said regulatory authorities would have a major role and that human trials could proceed after approval. The statement places the next decision outside the control of any one research institution or company. It also shows why the programme’s timeline cannot be assessed only through the date attached to the announcement. The quality and completeness of the evidence submitted to regulators will influence whether the intended schedule can be followed.
The institutional design behind Koch Vac also offers a view of how India’s indigenous vaccine pipeline is being built. IIT Bhubaneswar and the Institute of Life Sciences generated and jointly developed the candidate. The National Research Development Corporation facilitated the licensing agreement. Tech Invention is now responsible for advancing the programme towards optimisation, animal studies and the regulatory pathway. Each institution therefore occupies a different position in the chain from research to possible public use.
That chain matters especially for vaccines intended for large public-health programmes. A candidate may have a promising scientific design but still require decisions on formulation, adjuvants, production processes, quality control and deployment. The expert deliberation’s focus on large-scale suitability indicates that the programme is being considered beyond the laboratory. However, the supplied material does not establish whether manufacturing capacity, financing arrangements, procurement plans or distribution systems have been finalised.
The development also reflects the importance of location in India’s research ecosystem. Both IIT Bhubaneswar and the Institute of Life Sciences are contributing to a vaccine programme whose technology is now being taken forward by a Mumbai-based company. The project connects academic and life-science institutions in Bhubaneswar with a private-sector development partner and a national research-commercialisation agency. Its progress will therefore be relevant not only to TB policy but also to the question of how regional research capabilities become nationally deployable technologies.
The numbers currently available tell a restrained story. The programme has a licensing agreement from November 2025, a stated target for human trials in the second half of 2027, a proposed three-phase clinical pathway and a global TB death toll of 1.23 million in 2024. But there are no reported human-trial results, no confirmed regulatory approval, no announced launch date and no evidence in the supplied material that the candidate has yet demonstrated protection in people. The gap between these two sets of facts is the gap between development promise and public-health delivery.
For citizens, the immediate implication is not access to a new vaccine but the possibility of a future addition to the tools available against TB. Any such possibility remains conditional. The next meaningful milestones are the results of the animal studies, the completion of the required data package, the regulatory process and a formal decision on whether human trials may begin.
Koch Vac has therefore moved beyond an exclusively academic setting, but it has not yet entered clinical testing. The evidence confirms a structured transition involving IIT Bhubaneswar, the Institute of Life Sciences, Tech Invention and the National Research Development Corporation. What remains uncertain is whether the candidate will meet the scientific and regulatory requirements for human trials and, later, wider use. The development roadmap, rather than the 2027 target alone, will determine the programme’s next stage.
